NUVB

Business Context and Reporting Period

Nuvation Bio Inc. (NYSE: NUVB) is a global oncology company focused on developing novel small molecules and drug-drug conjugates. The filing covers the fiscal year ended December 31, 2025. The company transitioned to a commercial-stage entity in 2025 following the U.S. FDA approval of its lead product, IBTROZI (taletrectinib), on June 11, 2025, for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The company also completed the acquisition of AnHeart Therapeutics in April 2024, which brought taletrectinib and safusidenib into its pipeline.

Key Financial Metrics

Note: Debt includes a $150 million revenue interest financing liability and approximately $53 million in term loan principal (net of issuance costs).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 699% to $62.9 million, driven by the commercial launch of IBTROZI in the U.S. ($24.7 million) and a $30.3 million increase in collaboration revenue. The collaboration increase was primarily due to a $19.1 million increase in license revenue and a $6.3 million increase in R&D service revenue, including a $25.0 million regulatory milestone payment from Nippon Kayaku (NK) in Japan.
• Expense Reduction: Total costs and expenses decreased by $324.5 million to $276.0 million. This significant decrease was primarily due to the absence of the $425.1 million non-cash charge for acquired in-process research and development (IPR&D) recorded in 2024 following the AnHeart acquisition.
• Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased by $82.3 million to $151.6 million, reflecting the build-out of the commercial infrastructure for IBTROZI and one-time stock-based compensation charges related to FDA approval milestones. Research and Development (R&D) expenses increased by $16.0 million to $115.1 million.
• Financing Activity: In June 2025, the company secured $250 million in non-dilutive financing from Sagard, consisting of a $150 million revenue interest financing agreement and a $100 million senior secured term loan. $200 million was funded in 2025.

Guidance, Outlook, and Risks

Outlook and Management Commentary: Management believes existing cash, cash equivalents, and marketable securities ($529.2 million) are sufficient to fund operations for at least the next 12 months. The company is focused on maximizing the value of IBTROZI in the U.S. and supporting partners in Japan, China, and Europe. In January 2026, Nuvation Bio announced a partnership with Eisai Co., Ltd. to commercialize taletrectinib in Europe and other territories, receiving a €50 million upfront payment.

Key Risks and Contingencies:

• Commercialization Risk: Near-term prospects are heavily dependent on the successful commercialization of IBTROZI. The company has limited experience as a commercial entity, and market acceptance, reimbursement, and pricing remain uncertain.
• Debt Obligations: The company has significant debt service obligations. The revenue interest financing requires tiered royalty payments on U.S. net sales (5.5% up to $600M, 3.0% thereafter) with a "true-up" payment if 100% of the investment is not returned by 2043. The term loan bears interest at SOFR + 6.00% (with a 4.00% floor) and matures in 2030.
• Regulatory and Supply Chain: Regulatory approvals are subject to post-marketing requirements. The company relies on third-party manufacturers (including single-source suppliers in China) for API and drug product, creating supply chain risks.
• Legal Proceedings: A derivative lawsuit filed in July 2025 regarding director compensation was voluntarily discontinued by the plaintiff in November 2025 without prejudice.

Investor Verification Checklist

• IBTROZI Sales Trajectory: Verify the run-rate of U.S. product sales ($24.7M in ~6 months) against commercialization targets and the impact of the Sagard royalty obligations on net margins.
• Debt Covenants: Review the specific financial covenants in the Sagard Loan Agreement (e.g., maintaining $25M in cash) and the potential for early repayment triggers.
• Reimbursement Status: Confirm the status of formulary inclusion and reimbursement rates for IBTROZI in the U.S. and the impact of the new Eisai partnership on European market access.
• Supply Chain Diversification: Assess progress in qualifying a second source for taletrectinib API to mitigate reliance on single-source suppliers in China.
• Safusidenib Progress: Monitor enrollment and data readouts for the Phase 3 SIGMA study for safusidenib in IDH1-mutant astrocytoma.